Gamma distribution
	Disutility	SE	Alpha	Beta	Source
Complications or covariates
Female with type 1 diabetes and no complications	0.0236	0.008	8.70	0.003	Peasgood et al 45*
Adverse events‡
Severe hypoglycaemia	−0.002	−0.002	1	0.002	Peasgood et al 45
Diabetic ketoacidosis	−0.0091	−0.01	0.83	0.01	Peasgood et al 45*
Nephropathy§
Microalbuminuria	0				Assumption
Microalbuminuria	−0.017	0.01	2.89	0.01	Coffey et al 46
ESRD	−0.078	0.026	9	0.01	Coffey et al 46
Neuropathy§ (applied to the history of events)
Clinical neuropathy	−0.055	0.01	30.25	0.002	Coffey et al 46
Clinically confirmed neuropathy	−0.055	0.01	30.25	0.002	Coffey et al 46
Diabetic foot syndrome	−0.1042	−0.119	0.77	0.14	Peasgood et al 45
PAD with amputation	−0.1172	−0.055	4.54	0.03	Peasgood et al 45*
Retinopathy§ (applied to the history of events)
Background retinopathy	−0.0544	−0.023	5.59	0.01	Peasgood et al 45
Proliferative retinopathy	−0.0288	−0.026	1.23	0.02	Peasgood et al 45
Blindness	−0.208	0.013	256	0.001	Coffey et al 46
Cardiovascular§ (applied to the history of events)
MI (first year)	−0.065	0.03	4.69	0.01	Alva et al 47
MI (subsequent years)	−0.057	0.03	3.61	0.02	Alva et al 47
Heart failure	−0.101	0.032	9.96	0.010	Alva et al 47
Stroke	−0.165	0.035	22.22	0.007	Alva et al 47
Angina	−0.09	0.018	25	0.004	Clarke et al 48†

*A parameter value was not available in the author’s preferred statistical model.
†Value is presented in table 5 as ischaemic heart disease.
‡These disutilites are applied transiently to the number of these events in each year.
§These disutilites are applied to the history of ever having had one of these events.
ESRD, end-stage renal disease; MI, myocardial infarction; PAD, peripheral arterial disease.